Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

This study has been completed.
Sponsor:
Information provided by:
Changhai Hospital
ClinicalTrials.gov Identifier:
NCT00731198
First received: August 6, 2008
Last updated: August 31, 2010
Last verified: November 2009
Results First Received: September 14, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Prevention
Conditions: ERCP
Pancreatic Diseases
Bile Duct Diseases
Interventions: Drug: Drotaverine hydrochloride
Drug: Hyoscine-N-butylbromide

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Experimental Drotaverine hydrochloride
Active Comparator Hyoscine-N-butylbromide

Participant Flow:   Overall Study
    Experimental     Active Comparator  
STARTED     325     325  
COMPLETED     319     319  
NOT COMPLETED     6     6  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Experimental Drotaverine hydrochloride
Active Comparator Hyoscine-N-butylbromide
Total Total of all reporting groups

Baseline Measures
    Experimental     Active Comparator     Total  
Number of Participants  
[units: participants]
  325     325     650  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     205     197     402  
>=65 years     120     128     248  
Age  
[units: years]
Mean ± Standard Deviation
  56.98  ± 15.75     59.20  ± 16.14     58.09  ± 15.97  
Gender  
[units: participants]
     
Female     139     173     312  
Male     186     152     338  
Region of Enrollment  
[units: participants]
     
China     325     325     650  



  Outcome Measures

1.  Primary:   The Grades of the Number of Duodenal Contractions   [ Time Frame: Intra-procedure ]

2.  Secondary:   Cannulation Time   [ Time Frame: Intra-procedure ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

3.  Secondary:   Percentage of Successful Selective Cannulation   [ Time Frame: Intra-procedure ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   Frequency of Post-ERCP Complications   [ Time Frame: 48 hours after ERCP ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes

5.  Secondary:   Side Effects   [ Time Frame: Intra-procedure and 24 hours after ERCP ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   Yes


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Zhaoshen Li M.D.
Organization: Changhai Hospital, Second Military Medical University, Shanghai, China
phone: 86-21-81873271
e-mail: zhaoshenlismmu@gmail.com


No publications provided


Responsible Party: Zhaoshen Li, Changhai Hospital, Second Military Medical University
ClinicalTrials.gov Identifier: NCT00731198     History of Changes
Other Study ID Numbers: Changhai-080615
Study First Received: August 6, 2008
Results First Received: September 14, 2009
Last Updated: August 31, 2010
Health Authority: China: Food and Drug Administration